Pfizer turns back Mylan’s patent challenge to Sutent

Eric Palmer Pfizer execs can sigh with relief now that a federal court has backed the company's patents on kidney cancer drug Sutent. The med has become increasingly important to ...

Baxter wins FDA approval for another hemophilia drug

Damian Garde Baxter widened its hemophilia franchise on the eve of its breakup, winning FDA approval for a drug that treats a rare form of the bleeding disorder. FierceBiotech News

J&J Innovation taps Texas for its latest biotech startup incubator

Tracy Staton Johnson & Johnson taking its network of biopharma incubators to Texas in an expansion of its Janssen Labs initiative. FiercePharma News

U.K. watchdogs back Bayer’s Xarelto for heart attack patients

Carly Helfand Bayer's Xarelto, which has been cruising along since it joined a new class of warfarin replacement therapies on the market, has faced a rare stumbling block in acute ...

Google taps Boston brains for EU VC unit, Big Pharma VCs back Forendo, Swiss IPO halted

Nick Paul Taylor In this week's EuroBiotech Report, Google revealed further details of its $ 100 million (€79 million) European venture capital unit, which is hunting for ...

Will Pfizer rebid for AstraZeneca? Keep an eye on U.S. midterm election for clues

Tracy Staton Will Pfizer come back at AstraZeneca? That's been the question of the summer, especially since the U.S. Treasury Department rolled out new rules for tax-inversion deals. FiercePharma ...

Despite a mid-stage miss, Cytokinetics is taking its ALS drug toward Phase III

Damian Garde Earlier this year, Cytokinetics tanked as its lead prospect, a treatment for amyotrophic lateral sclerosis (ALS), missed its primary endpoint and a slew of secondary goals ...

Bristol-Myers catches a break as Indian agency delays Sprycel patent decision

Eric Palmer Prime Minister Narendra Modi got an ear full from both constituents and the U.S. drug industry about India's approach to drug patents during his first visit to the U.S. ...

Astellas backs out of a $760M Alzheimer’s deal with CoMentis

Damian Garde Astellas and CoMentis are calling it quits on their partnership in Alzheimer's disease, as the Japanese drugmaker walks away from a deal valued at up to $ 760 million. FierceBiotech ...

Merck and Roche prep breast cancer data for promising PD-1 drugs

Emily Mullin As fervor surrounding a new class of cancer drugs builds, drug giants Merck and Roche are set to roll out new data for their opposing immunotherapy drugs for breast cancer ...

Kalydeco in R117H patients? As AdComm nears, Vertex drug faces doubts

Carly Helfand Vertex' orphan drug Kalydeco boasts a comparatively small patient pool that the drugmaker is trying to swell, with an eye on adding cystic fibrosis patients with the ...

Adaptimmune’s novel cancer treatment posts promising early results

Damian Garde Adaptimmune's pioneering approach to cancer immunotherapy has charted some impressive results in a small study. And while the biotech is quick to point out that it's ...
Page 2 of 612345...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS